Floatz logo

Allo-Revcar01-T

AML (Acute Myelogenous Leukemia)

AvenCell Therapeutics, Inc.Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

684 Active assets in the AML (Acute Myelogenous Leukemia) cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB
Posaconazole
AstraZeneca
Phase 4BBB

View all 50 →

Same molecule, other indications

Allo-Revcar01-T is also rated in:

B-cell non-Hodgkin lymphomaDormant
D
Indicative ·
30 / 100
View asset →
hematopoietic and lymphoid cell neoplasmDormant
D
Indicative ·
30 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
D
Indicative ·
28 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →